LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

FORM PTO-1449

ATTY. DOCKET NO.	APPLICATION NO.
05371.0031.US02	09/084,471
APPLICANT	
Patricia D. MURPHY, *et al.*	
FILING DATE	**GROUP**
May 22, 1998	~~1643~~ 1655

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SZ		4,458,066	7/1984	Caruthers et al.	536	27	
		5,445,934	8/1995	Fodor et al.	435	6	
		5,510,270	4/1996	Fodor et al.	436	518	
		5,547,839	8/1996	Dower et al.	435	6	
		5,593,840	1/1997	Bhatnagar et al.	435	6	

FOREIGN PATENT DOCUMENTS

				COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

SZ	1	Beaucage, S.L. and Caruthers, M.H., "Deoxynucleoside Phosphoramidites – A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," *Tetrahedron Letters* 22:1859-1862 (1981)
		Bertwistle, D. and Ashworth, A., "Functions of the *BRCA1* and *BRCA2* genes," *Current Opinion in Genetics & Development* 8:14-20 (1998)
		Conner et al., "Detection of sickle cell β^s-globin allele by hybridization with synthetic oligonucleotides," *Proc. Natl. Acad. Sci. USA* 80:278-282 (1983)
		Couch et al., "BRCA2 germline mutations in male breast cancer cases and breast cancer families," Nature Genetics 13:123-125 (1996)
		Crooke, S., "Therapeutic Applications of Oligonucleotides," *Annu. Rev. Pharmacol. Toxicol.* 32:329-376 (1992)
		Friend et al., Breast cancer information on the web, *Nature Genetics* 11:238-239 (1995)
		Holt et al., "Growth retardation and tumour inhibition by *BRCA1*," *Nature Genetics* 12:298-302 (1996)
		Jensen et al., "Characterization of Baculovirus-Expressed Human α and β Platelet-Derived Growth Factor Receptors," *Biochemistry* 31:10887-10892 (1992)
		Jensen et al., "BRCA1 is secreted and exhibits properties of a granin," *Nature Genetics* 12:303-308 (1996)
		Katagiri et al., "Multiple Possible Sites of BRCA2 Interacting With DNA Repair Protein RAD51," *Genes, Chromosomes & Cancer* 21:217-222 (1998)

52		Landegren et al., "DNA Diagnostics – Molecular Techniques and Automation," *Science* 242:229-237 (1988)
		Landegren et al., "A Ligase-Mediated Gene Detection Technique," *Science* 241:1077-1021 (1988)
		Miki et al., "A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene *BRCA1*," *Science* 266:66-71 (1994)
		Phelan et al., "Mutation analysis of the *BRCA2* gene in 49 site-specific breast cancer families," *Nature Genetics* 13:120-122 (1996)
		Robinson-Benion, C. and Holt, J., "[23] Antisense Techniques," *Methods in Enzymology* 254:363-375 (1995)
		Rowell et al., "Invited Editorial: Inherited Predisposition to Breast and Ovarian Cancer," *Am. J. Hum. Genet.* 55:861-865 (1994)
		Saiki et al., "A Novel Method for the Detection of Polymorphic Restriction Sites by Cleavage of Oligonucleotide Probes: Application to Sickle-Cell Anemia," *Bio/Technology* 3:1008-1012 (1985)
		Schubert et al., "BRCA2 in American Families With Four or More Cases of Breast or Ovarian Cancer: Recurrent and Novel Mutations, Variable Expression, Penetrance, and the Possibility of Families Whose Cancer is Not Attributable to BRCA1 or BRCA2," *Am. J. Hum. Genet.* 60:1031-1040 (1997)
		Sharan et al., "Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking *BRCA2*," *Nature* 386:804-810 (1997)
		Tavtigian et al., "The complete *BRCA2* gene and mutations in chromosome 13q-linked kindreds," *Nature Genetics* 12:333-337 (1996)
		Teng et al., "Low incidence of *BRCA2* mutations in breast carcinoma and other cancers," *Nature Genetics* 13:241-244 (1996)
		Thompson et al., "Decreased expression of *BRCA1* accelerates growth and is often present during sporadic breast cancer progression," *Nature Genetics* 9:444-449 (1995)
		Wooster et al., "Identification of the breast cancer susceptibility gene *BRCA2*," *Nature* 378:789-792 (1995)
		Wooster et al., "Localization of a Breast Cancer Susceptibility Gene, *BRCA2*, to Chromosome 13q12-13," *Science* 265:2088-2090 (1994)
		Zhang et al., "BRCA1, BRCA2, and DNA Damage Response: Collision or Collusion?," *Cell* 92:433-436 (1998)

EXAMINER	DATE CONSIDERED
D. Ekhoner	3-6-2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.